Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.53 |
| ▸ | FURIN | P09958 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808012 | 0.90 | NPC1 (0.71) | F10PRSS1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL6806801 | 0.90 | MAPT (0.62) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL7477445 | 0.81 | F10 (0.71) | F10PRSS1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL6808723 | 0.81 | SMN1; SMN2 (0.60) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL6808206 | 0.80 | NPC1 (0.74) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL4293714 | 0.79 | MAPT (0.78) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL6809487 | 0.79 | GAA (0.62) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL10701012 | 0.76 | MAPT (0.78) | MAPTNPC1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL2957651 | 0.76 | MAPT (0.68) | MAPTNPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL7475225 | 0.75 | F10 (1.00) | F10PRSS1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | F10 64/4885PRSS1 1089/4885MAPT 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.